Literature DB >> 19718058

Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.

T Ikezoe, K Togitani, N Komatsu, M Isaka, A Yokoyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19718058     DOI： 10.1038/bmt.2009.217

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  19 in total

Review 1.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

2.  Improvement of high serum levels of biomarkers of endothelial injury after allogeneic hematopoietic SCT with pre-existing severe hepatitis using recombinant human soluble thrombomodulin.

Authors:  T Saito; Y Inoue; K Sato; Y Tsuruoka; R Shigefuku; H Ikeda; C Okuse; M Takahashi; I Miura
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

3.  Heterogeneous response to recombinant thrombomodulin by grade of sinusoidal obstructive syndrome after pediatric stem cell transplantation.

Authors:  J Inagaki; K Kurauchi; R Fukano; M Noguchi; J Okamura
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

4.  Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  S Yamamoto; R Matsuno; Y Sugishita; R Kaneko; N Okamoto; M Koganesawa; S Fujita; K Akiyama; D Toyama; K Isoyama
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

5.  Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.

Authors:  Kimikazu Yakushijin; Katsuya Yamamoto; Keiji Kurata; Yoshiharu Miyata; Seiji Kakiuchi; Hideo Tomioka; Yuriko Kawamori-Iwamoto; Yumiko Inui; Yukinari Sanada; Atsuo Okamura; Tohru Murayama; Hiroshi Matsuoka; Hironobu Minami
Journal:  Int J Hematol       Date:  2013-01-08       Impact factor: 2.490

Review 6.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

7.  Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis.

Authors:  T Ikezoe; J Yang; C Nishioka; K Umezawa; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

Review 8.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

9.  Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen.

Authors:  T Ikezoe; J Yang; C Nishioka; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2014-09-22       Impact factor: 5.483

10.  The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model.

Authors:  T Ikezoe; J Yang; C Nishioka; B Pan; K Xu; M Furihata; K Nakamura; H Yurimoto; Y Sakai; G Honda; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.